| pubmed-article:16866989 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16866989 | lifeskim:mentions | umls-concept:C0027651 | lld:lifeskim |
| pubmed-article:16866989 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:16866989 | lifeskim:mentions | umls-concept:C0034802 | lld:lifeskim |
| pubmed-article:16866989 | lifeskim:mentions | umls-concept:C0038952 | lld:lifeskim |
| pubmed-article:16866989 | lifeskim:mentions | umls-concept:C0004083 | lld:lifeskim |
| pubmed-article:16866989 | lifeskim:mentions | umls-concept:C1516514 | lld:lifeskim |
| pubmed-article:16866989 | lifeskim:mentions | umls-concept:C1521871 | lld:lifeskim |
| pubmed-article:16866989 | lifeskim:mentions | umls-concept:C2348519 | lld:lifeskim |
| pubmed-article:16866989 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:16866989 | pubmed:dateCreated | 2006-7-26 | lld:pubmed |
| pubmed-article:16866989 | pubmed:abstractText | Chromogenic in situ hybridization (CISH) was used to detect amplification of the epidermal growth factor receptor (EGFR) gene in tissue microarrays of tumours derived from 287 patients with grade II-IV diffuse astrocytomas. Amplification was found in 32% of the tumours with a highly significant association with histological grade (4% in grade II, 21% in grade III and 39% in grade IV; P < 0.001). Amplification of the EGFR gene was more common in primary than in secondary glioblastomas (41%vs. 16%, P = 0.033). Overexpression of EGFR mRNA and protein (wild-type and vIII variant) was found to correlate with EGFR gene amplification (P = 0.028, P = 0.035 and P = 0.014 respectively), but wild-type EGFR protein was also frequently overexpressed in tumours without EGFR gene amplification. Patients with older age (P < 0.001) and tumours with lack of p53 overexpression (P = 0.03) and higher apoptosis rate (P < 0.001) had significantly more EGFR gene amplifications than their counterparts. No such correlation with apoptosis was found in glioblastomas. The survival of patients with EGFR gene-amplified grade III tumours was significantly shorter than in those with grade III non-amplified tumours (P = 0.03). No such difference was noted in glioblastomas (grade IV tumours). Our data verify the central role of EGFR in the pathobiology of astrocytic tumours, and highlight the advantages of CISH as a simple and practical assay to screen for EGFR gene amplification in astrocytic tumours. | lld:pubmed |
| pubmed-article:16866989 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16866989 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16866989 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16866989 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16866989 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16866989 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16866989 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16866989 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16866989 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16866989 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:16866989 | pubmed:issn | 0305-1846 | lld:pubmed |
| pubmed-article:16866989 | pubmed:author | pubmed-author:TannerMM | lld:pubmed |
| pubmed-article:16866989 | pubmed:author | pubmed-author:HelinHH | lld:pubmed |
| pubmed-article:16866989 | pubmed:author | pubmed-author:EleniusKK | lld:pubmed |
| pubmed-article:16866989 | pubmed:author | pubmed-author:IsolaJJ | lld:pubmed |
| pubmed-article:16866989 | pubmed:author | pubmed-author:HaapasaloHH | lld:pubmed |
| pubmed-article:16866989 | pubmed:author | pubmed-author:HaapasaloJJ | lld:pubmed |
| pubmed-article:16866989 | pubmed:author | pubmed-author:JunttilaT TTT | lld:pubmed |
| pubmed-article:16866989 | pubmed:author | pubmed-author:JärveläTimoT | lld:pubmed |
| pubmed-article:16866989 | pubmed:author | pubmed-author:JärveläSallyS | lld:pubmed |
| pubmed-article:16866989 | pubmed:author | pubmed-author:JärvelläSS | lld:pubmed |
| pubmed-article:16866989 | pubmed:author | pubmed-author:JärvelläTT | lld:pubmed |
| pubmed-article:16866989 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16866989 | pubmed:volume | 32 | lld:pubmed |
| pubmed-article:16866989 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16866989 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16866989 | pubmed:pagination | 441-50 | lld:pubmed |
| pubmed-article:16866989 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:16866989 | pubmed:meshHeading | pubmed-meshheading:16866989... | lld:pubmed |
| pubmed-article:16866989 | pubmed:meshHeading | pubmed-meshheading:16866989... | lld:pubmed |
| pubmed-article:16866989 | pubmed:meshHeading | pubmed-meshheading:16866989... | lld:pubmed |
| pubmed-article:16866989 | pubmed:meshHeading | pubmed-meshheading:16866989... | lld:pubmed |
| pubmed-article:16866989 | pubmed:meshHeading | pubmed-meshheading:16866989... | lld:pubmed |
| pubmed-article:16866989 | pubmed:meshHeading | pubmed-meshheading:16866989... | lld:pubmed |
| pubmed-article:16866989 | pubmed:meshHeading | pubmed-meshheading:16866989... | lld:pubmed |
| pubmed-article:16866989 | pubmed:meshHeading | pubmed-meshheading:16866989... | lld:pubmed |
| pubmed-article:16866989 | pubmed:meshHeading | pubmed-meshheading:16866989... | lld:pubmed |
| pubmed-article:16866989 | pubmed:meshHeading | pubmed-meshheading:16866989... | lld:pubmed |
| pubmed-article:16866989 | pubmed:meshHeading | pubmed-meshheading:16866989... | lld:pubmed |
| pubmed-article:16866989 | pubmed:meshHeading | pubmed-meshheading:16866989... | lld:pubmed |
| pubmed-article:16866989 | pubmed:meshHeading | pubmed-meshheading:16866989... | lld:pubmed |
| pubmed-article:16866989 | pubmed:meshHeading | pubmed-meshheading:16866989... | lld:pubmed |
| pubmed-article:16866989 | pubmed:meshHeading | pubmed-meshheading:16866989... | lld:pubmed |
| pubmed-article:16866989 | pubmed:meshHeading | pubmed-meshheading:16866989... | lld:pubmed |
| pubmed-article:16866989 | pubmed:meshHeading | pubmed-meshheading:16866989... | lld:pubmed |
| pubmed-article:16866989 | pubmed:meshHeading | pubmed-meshheading:16866989... | lld:pubmed |
| pubmed-article:16866989 | pubmed:meshHeading | pubmed-meshheading:16866989... | lld:pubmed |
| pubmed-article:16866989 | pubmed:meshHeading | pubmed-meshheading:16866989... | lld:pubmed |
| pubmed-article:16866989 | pubmed:meshHeading | pubmed-meshheading:16866989... | lld:pubmed |
| pubmed-article:16866989 | pubmed:meshHeading | pubmed-meshheading:16866989... | lld:pubmed |
| pubmed-article:16866989 | pubmed:meshHeading | pubmed-meshheading:16866989... | lld:pubmed |
| pubmed-article:16866989 | pubmed:meshHeading | pubmed-meshheading:16866989... | lld:pubmed |
| pubmed-article:16866989 | pubmed:meshHeading | pubmed-meshheading:16866989... | lld:pubmed |
| pubmed-article:16866989 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16866989 | pubmed:articleTitle | Amplification of the epidermal growth factor receptor in astrocytic tumours by chromogenic in situ hybridization: association with clinicopathological features and patient survival. | lld:pubmed |
| pubmed-article:16866989 | pubmed:affiliation | Department of Pathology, Tampere University Hospital, Tampere, Finland. sally.jarvela@sci.fi | lld:pubmed |
| pubmed-article:16866989 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16866989 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16866989 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16866989 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16866989 | lld:pubmed |
